{"gene":"BRAF","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2002,"finding":"BRAF somatic missense mutations occur in 66% of malignant melanomas, predominantly within the kinase domain; mutated BRAF proteins (including V599E/V600E) have elevated kinase activity and are transforming in NIH3T3 cells; RAS function is not required for growth of cancer cell lines with the V600E mutation, establishing BRAF as a constitutively active, RAS-independent oncogenic kinase.","method":"Genome-wide sequencing of cancer samples, in vitro kinase activity assays, NIH3T3 transformation assays, cancer cell line growth studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis, transformation assay, and genetic epistasis (RAS independence); foundational study replicated extensively across many labs","pmids":["12068308"],"is_preprint":false},{"year":2005,"finding":"BRAF mutation (V600E) confers selective sensitivity to MEK inhibition regardless of tissue lineage; pharmacological MEK inhibition completely abrogated tumor growth in BRAF-mutant xenografts, correlating with downregulation of cyclin D1 and G1 arrest, establishing BRAF-mutant tumors as exquisitely MEK-dependent.","method":"Small-molecule MEK inhibitor treatment of cell lines and xenografts stratified by BRAF/RAS mutation status; cyclin D1 expression analysis; cell-cycle analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic stratification, pharmacologic inhibition in vitro and in vivo with defined molecular readouts; replicated in subsequent studies","pmids":["16273091"],"is_preprint":false},{"year":2013,"finding":"BRAF is phosphorylated at Ser729 by AMP-activated protein kinase (AMPK); this phosphorylation promotes association of BRAF with 14-3-3 proteins and disrupts its interaction with the KSR1 scaffolding protein, leading to attenuation of MEK-ERK signaling, impaired keratinocyte proliferation, and suppression of BRAF inhibitor-induced ERK hyperactivation.","method":"In vitro kinase assay (AMPK phosphorylation of BRAF), co-immunoprecipitation (BRAF–14-3-3 and BRAF–KSR1 interactions), site-specific mutagenesis, cell-cycle analysis, mouse skin epidermal hyperplasia model","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay identifying specific phosphorylation site, reciprocal co-IP for binding partners, mutagenesis, and in vivo mouse model in a single study","pmids":["24095280"],"is_preprint":false},{"year":2015,"finding":"Oncogenic BRAF V600E upregulates the ketogenic enzyme HMGCL via the transcription factor Oct-1, leading to increased intracellular acetoacetate levels; acetoacetate selectively enhances binding of BRAF V600E (but not wild-type BRAF) to MEK1, promoting MEK-ERK signaling and tumor growth — a mutation-specific metabolic rewiring mechanism.","method":"Co-immunoprecipitation (BRAF V600E–MEK1 binding with/without acetoacetate), shRNA knockdown of HMGCL, metabolite measurement, Oct-1 transcriptional analysis, xenograft tumor growth assay","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution of metabolite-enhanced BRAF–MEK1 binding, mutagenesis-like comparison of V600E vs WT, multiple orthogonal methods in single study","pmids":["26145173"],"is_preprint":false},{"year":2018,"finding":"PLX8394, a next-generation RAF inhibitor, inhibits ERK signaling by specifically disrupting BRAF-containing dimers (BRAF homodimers and BRAF-CRAF heterodimers) but not CRAF homodimers or ARAF-containing dimers; differences in the N-terminal portion of the kinase domain among RAF isoforms are responsible for this differential vulnerability; PLX8394 inhibits ERK signaling in tumors driven by dimeric BRAF mutants (fusions, splice variants) as well as V600 monomers.","method":"Cell-based signaling assays, RAF dimer disruption assays, structure-activity analysis of RAF isoform sequences, mutagenesis, cancer cell line panels with diverse BRAF alterations","journal":"Nature Medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection of dimer selectivity with isoform mutagenesis and multiple BRAF-variant cell models in a single focused study","pmids":["30559419"],"is_preprint":false},{"year":2020,"finding":"Ponatinib binds the BRAF dimer and stabilizes a distinct αC-helix conformation through interaction with a previously unrevealed allosteric site; based on this structural insight, PHI1 was developed as a BRAF dimer-selective inhibitor that shows enhanced inhibition of the second protomer when the first is occupied (positive cooperativity within the dimer).","method":"Structural binding studies, αC-helix conformation analysis, development of PHI1 inhibitor, cellular selectivity assays for BRAF monomers vs. dimers","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural characterization of allosteric site combined with medicinal chemistry validation and cellular functional assays in single study","pmids":["32873792"],"is_preprint":false},{"year":2019,"finding":"BRAF inhibitors binding the V600E-mutated BRAF catalytic pocket stabilize an intermediate, inactive kinase conformation that unexpectedly enhances binary RAS:BRAF interactions independently of RAF dimerization in melanoma cells; this allosteric intramolecular communication between the kinase and RAS-binding domains may further promote paradoxical kinase activation.","method":"Luciferase-based BRAF conformation biosensors, RAS:RAF binary interaction assays, structurally diverse inhibitor panel, melanoma cell lines","journal":"Science Advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel biosensor approach with multiple inhibitors, but mechanistic interpretation (allosteric communication) is partially inferred; single lab","pmids":["31453322"],"is_preprint":false},{"year":2016,"finding":"BRAF V600E drives melanoma cell invasion by inducing phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics (F-actin/cortactin foci, membrane protrusion) and matrix metalloprotease secretion, respectively; BRAF V600E inhibition blocks these invasion activities in vitro and reduces cortactin foci in a murine melanoma model and patient biopsies.","method":"F-actin/cortactin foci assays, ECM degradation assay, BRAF inhibitor treatment, phospho-protein analysis, genome-wide expression profiling, murine BRAF V600E model, patient biopsy analysis","journal":"Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined molecular mechanism (ERK-mediated phosphorylation of cortactin/Exo70) with functional readouts in vitro, in vivo, and in patient tissue; single lab","pmids":["27210749"],"is_preprint":false},{"year":2017,"finding":"Expression of the kinase-inactive Braf D631A (human D594A) isoform in mice triggers lung adenocarcinoma in vivo, acting as an initiating oncogenic event; co-expression with Kras G12V markedly enhances tumor initiation via Craf kinase activity; wild-type Braf kinase sustains Kras/Braf D631A-driven tumors, and its ablation induces excessive MAPK signaling causing oncogenic toxicity that can be rescued by Mek inhibition.","method":"Conditional knock-in mouse model (Cre-mediated), genetic epistasis (wild-type Braf allele deletion, Craf activity requirement), MEK inhibitor rescue experiments, MAPK pathway signaling analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous mouse genetic epistasis with multiple allele combinations, pharmacological rescue, and in vivo oncogenesis readout; comprehensive mechanistic dissection in single study","pmids":["28783725"],"is_preprint":false},{"year":2017,"finding":"BRAF gene internal deletions involving the Ras-binding domain (exons 2–8) represent a mechanism of acquired resistance to dabrafenib/trametinib in melanoma; these deletions are analogous to BRAF fusions and splice variants that reactivate RAS-RAF-MEK-ERK signaling by removing the RAS-binding domain.","method":"Pre- and post-treatment tumor biopsy sequencing (foundation medicine panel), large melanoma cohort analysis (next-generation sequencing)","journal":"Pigment Cell & Melanoma Research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genomic characterization with mechanistic inference from structural analogy to known splice variants; no direct functional reconstitution of the deletion construct","pmids":["29171936"],"is_preprint":false},{"year":2017,"finding":"A somatic BRAF splicing mutation (9 bp duplication encoding insertion of 3 amino acids in the N-terminal kinase domain lobe, p.Arg506_Lys507insLeuLeuArg) found in LCH cases enhances MAPK pathway activation in HEK293 cells and is not inhibited by vemurafenib but is inhibited by the dimer-targeting inhibitor PLX8394, indicating this mutant signals as a dimer.","method":"Whole exome sequencing, transient expression in HEK293 cells, MAPK pathway activation assays, BRAF inhibitor treatment (vemurafenib vs PLX8394)","journal":"Molecular Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — cell-based functional validation of mutant with inhibitor sensitivity, but single lab and limited mechanistic detail in abstract","pmids":["28679432"],"is_preprint":false},{"year":2012,"finding":"Anti-BRAF autoantibodies targeting the BRAF catalytic domain were identified in rheumatoid arthritis patients; these autoantibodies stimulate BRAF activity, in contrast to anti-PAD4 autoantibodies which are inhibitory.","method":"Protein array screening of 8000 human proteins with RA patient sera, validation of BRAF as autoantigen, functional assay of antibody effect on BRAF kinase activity","journal":"Autoimmunity Reviews","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, functional claim (stimulation of BRAF activity) mentioned briefly in abstract without detailed mechanistic follow-up","pmids":["22349616"],"is_preprint":false},{"year":2019,"finding":"BRAF oncogene drives loss of RIPK3 expression in cancer cells, suppressing necroptosis sensitivity; inhibition of BRAF can rescue RIPK3 expression and restore necroptosis sensitivity.","method":"Genome-wide bioinformatics analysis of 941 cancer cell line necroptosis sensitivity screen correlated with gene expression and mutation data; pharmacological BRAF inhibition with RIPK3 re-expression readout","journal":"PLoS Biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — correlational bioinformatics with pharmacological rescue as primary evidence; mechanism of BRAF-driven RIPK3 silencing not directly established","pmids":["30157175"],"is_preprint":false},{"year":2013,"finding":"BRAF V600E mutations drive constitutive MAPK pathway activation in ameloblastoma cells in vitro; the BRAF inhibitor vemurafenib potently inhibits proliferation and MAPK activation in an ameloblastoma-derived cell line.","method":"Allele-specific PCR, Sanger sequencing, VE1 immunohistochemistry, cell proliferation assay with vemurafenib, phospho-MAPK western blot in cell line","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutation identification with functional validation in cell line model; two orthogonal detection methods plus inhibitor functional assay","pmids":["24993163"],"is_preprint":false},{"year":2015,"finding":"BRAF V600E inhibition attenuates TERT expression and TERT promoter activity in BRAF V600E/TERT promoter double-mutant glioma cells but not in BRAF V600E-only cells; this occurs through downregulation of ETS1 phosphorylation and expression, with ChIP confirming a functional role for ETS1 at the TERT promoter.","method":"BRAF inhibitor treatment, qRT-PCR, Western blot (ETS1 expression/phosphorylation), ChIP, luciferase TERT promoter reporter assay, ETS1 knockdown experiments","journal":"Acta Neuropathologica Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP, reporter assay, KD, inhibitor) establishing BRAF→ERK→ETS1→TERT axis in single lab study","pmids":["31391125"],"is_preprint":false},{"year":2023,"finding":"SRC kinases are systematically activated in BRAF V600E colorectal cancer following BRAF ± EGFR targeted inhibition; SRC drives resistance independently of ERK signaling by inducing transcriptional reprogramming through β-catenin; this SRC activation is mediated by an autocrine prostaglandin E2 (COX2) loop, and COX2 inhibition combined with BRAF + EGFR targeting promotes durable tumor suppression in PDX models.","method":"High-throughput kinase activity mapping, cell-based signaling assays, β-catenin transcriptional reporter, COX2/prostaglandin E2 pathway analysis, patient-derived xenograft models","journal":"Nature Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods identifying SRC-β-catenin resistance axis and COX2 autocrine loop; in vivo PDX validation; single lab","pmids":["36759733"],"is_preprint":false},{"year":2019,"finding":"In BRAF V600E-driven tumors, adaptive resistance to dual BRAF/MEK inhibition occurs through transcriptional upregulation of FGF1, which autocrinally activates FGFR to reactivate ERK; FGFR inhibition overcomes this resistance in cell lines and patient-derived xenograft models.","method":"Resistant cell line generation, pharmacologic synthetic lethal screen, FGF1 transcriptional analysis, FGFR inhibitor rescue in cells and PDX models, serum FGF1 clinical correlation","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanism established through resistant line generation, transcriptomic analysis, and PDX validation; single lab","pmids":["31515463"],"is_preprint":false},{"year":2020,"finding":"Dabrafenib (BRAF kinase inhibitor) and other BRAF/MEK/ERK pathway inhibitors protect against cisplatin- and noise-induced hearing loss in mice; oral dabrafenib represses ERK phosphorylation in cochlear cells, identifying BRAF-ERK signaling as a mediator of ototoxicity.","method":"Small-molecule kinase inhibitor screen in inner ear cell line, cochlear explant hair cell death assay, oral dabrafenib treatment in adult mice, ERK phosphorylation analysis in cochlear cells, audiological hearing loss assessment","journal":"Science Advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological evidence linking BRAF-ERK pathway to cochlear cell survival, multiple model systems; single lab","pmids":["33268358"],"is_preprint":false},{"year":2017,"finding":"BRAF exists as a pool of at least three protein isoforms (BRAF-ref, BRAF-X1, BRAF-X2) differing in their C-terminal coding sequences; BRAF-X1 and BRAF-ref are both translated and together account for BRAF functional activities, while endogenous BRAF-X2 protein is selectively targeted for degradation by the ubiquitin-proteasome pathway.","method":"RNA-seq analysis of >4800 cancer patients, isoform-specific protein detection, proteasome inhibition experiments, functional activity assays of isoforms","journal":"Molecular Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein-level isoform characterization with degradation mechanism (proteasome) validated biochemically; large dataset plus functional follow-up","pmids":["28454577"],"is_preprint":false}],"current_model":"BRAF is a RAS-regulated serine/threonine kinase that, when activated (most commonly by the V600E mutation), signals constitutively as an active monomer (V600E) or as RAS-independent dimers (other oncogenic mutants and fusions) through MEK-ERK to drive proliferation, survival, invasion (via ERK-mediated cortactin/Exo70 phosphorylation), and metabolic rewiring (via Oct-1–HMGCL–acetoacetate–MEK1 axis); its activity is negatively regulated by AMPK-mediated phosphorylation at Ser729, which promotes 14-3-3 binding and disrupts KSR1 scaffolding; pharmacological inhibitors variably target monomers or dimers depending on their mechanism, and resistance arises through FGFR autocrine loops, RAS-binding domain deletions, and other MAPK reactivation mechanisms."},"narrative":{"mechanistic_narrative":"BRAF is a RAS-regulated serine/threonine kinase that functions as a core node of the MAPK (RAS-RAF-MEK-ERK) cascade and is a major oncogenic driver, most prominently through the recurrent V600E mutation that elevates kinase activity, transforms cells, and signals constitutively without requiring upstream RAS function [PMID:12068308]. BRAF-mutant tumors across lineages are exquisitely dependent on downstream MEK, such that MEK inhibition arrests proliferation via cyclin D1 downregulation and G1 arrest [PMID:16273091], and the same dependence drives MAPK activation in diverse tumor contexts including ameloblastoma [PMID:24993163]. The oncogenic output of BRAF V600E extends beyond proliferation: ERK-mediated phosphorylation of cortactin and the exocyst subunit Exo70 reprograms actin dynamics and matrix metalloprotease secretion to drive invasion [PMID:27210749], an ETS1-dependent axis sustains TERT promoter activity [PMID:31391125], and a mutation-specific metabolic loop in which Oct-1 drives HMGCL expression and acetoacetate selectively enhances V600E-MEK1 binding amplifies signaling [PMID:26145173]. BRAF activity is negatively regulated by AMPK phosphorylation at Ser729, which promotes 14-3-3 association, disrupts KSR1 scaffolding, and attenuates MEK-ERK signaling [PMID:24095280]. Distinct oncogenic mechanisms operate for non-V600 alterations: kinase-inactive BRAF can initiate tumorigenesis through CRAF, with wild-type BRAF kinase paradoxically required to restrain excessive MAPK output [PMID:28783725], and RAS-binding-domain deletions, splice insertions, and fusions activate signaling as RAF dimers that resist V600-monomer inhibitors but are blocked by dimer-disrupting agents [PMID:29171936, PMID:28679432, PMID:30559419]. Structural work defines the basis for monomer- versus dimer-selective inhibition, including an allosteric αC-helix site supporting positive cooperativity within the dimer [PMID:32873792] and inhibitor-stabilized inactive conformations that enhance RAS:BRAF binding [PMID:31453322]. Adaptive and acquired resistance to pathway inhibition arises through autocrine FGF1-FGFR reactivation of ERK [PMID:31515463] and an ERK-independent SRC-β-catenin axis sustained by a COX2/prostaglandin E2 loop [PMID:36759733].","teleology":[{"year":2002,"claim":"Established that BRAF is a frequently mutated oncogenic kinase whose activating mutations render it constitutively active and independent of upstream RAS, defining it as a direct cancer driver rather than a passive relay.","evidence":"Genome-wide cancer sequencing with in vitro kinase assays, NIH3T3 transformation, and RAS-independence growth studies in melanoma","pmids":["12068308"],"confidence":"High","gaps":["Did not resolve how different mutation classes signal (monomer vs dimer)","No structural basis for elevated kinase activity"]},{"year":2005,"claim":"Showed that BRAF mutation creates a lineage-independent therapeutic dependence on MEK, framing BRAF-mutant tumors as targetable through the downstream MAPK module.","evidence":"MEK inhibitor treatment of cell lines and xenografts stratified by BRAF/RAS status, with cyclin D1 and cell-cycle readouts","pmids":["16273091"],"confidence":"High","gaps":["Did not address acquired resistance","MEK dependence shown but BRAF-direct inhibition strategy not yet defined"]},{"year":2013,"claim":"Identified a physiological brake on BRAF: AMPK phosphorylation at Ser729 reroutes BRAF away from KSR1 scaffolding toward 14-3-3, attenuating MAPK output and constraining BRAF-inhibitor-induced ERK hyperactivation.","evidence":"In vitro AMPK kinase assay, reciprocal co-IP of 14-3-3 and KSR1, site mutagenesis, and a mouse epidermal hyperplasia model","pmids":["24095280"],"confidence":"High","gaps":["Relevance of Ser729 regulation in tumors with constitutive V600E unclear","How AMPK status modulates inhibitor response in patients not established"]},{"year":2015,"claim":"Revealed a mutation-specific metabolic feed-forward loop in which BRAF V600E induces ketogenic HMGCL via Oct-1, and the resulting acetoacetate selectively strengthens V600E-MEK1 binding to amplify signaling.","evidence":"Co-IP of V600E-MEK1 with/without acetoacetate, HMGCL shRNA, metabolite measurement, and xenograft growth","pmids":["26145173"],"confidence":"High","gaps":["Structural basis for acetoacetate-enhanced binding not resolved","Generalizability to non-melanoma V600E tumors untested"]},{"year":2016,"claim":"Connected BRAF V600E signaling to the invasive phenotype by showing ERK-driven phosphorylation of cortactin and Exo70 controls actin dynamics and MMP secretion.","evidence":"F-actin/cortactin foci and ECM degradation assays, phospho-protein analysis, BRAF inhibition, murine model and patient biopsies","pmids":["27210749"],"confidence":"Medium","gaps":["Single lab","Direct kinase-substrate relationship of ERK to Exo70/cortactin inferred from phospho-readouts"]},{"year":2017,"claim":"Demonstrated that kinase-inactive BRAF can initiate tumorigenesis through CRAF and that wild-type BRAF kinase paradoxically restrains MAPK signaling, exposing dimer- and isoform-dependent complexity in BRAF oncogenesis.","evidence":"Conditional knock-in mouse genetics with allele combinations, CRAF-activity epistasis, and MEK-inhibitor rescue","pmids":["28783725"],"confidence":"High","gaps":["Molecular mechanism of wild-type BRAF restraining MAPK not fully defined","Human relevance of D594A-class mutants in this model untested"]},{"year":2017,"claim":"Characterized RAS-binding-domain-removing alterations — internal deletions and splice insertions — as dimer-driven signaling mechanisms underlying targeted-therapy resistance.","evidence":"Pre/post-treatment tumor sequencing for deletions; HEK293 expression and inhibitor (vemurafenib vs PLX8394) testing of an LCH splice insertion","pmids":["29171936","28679432"],"confidence":"Medium","gaps":["Deletion constructs not functionally reconstituted","Limited mechanistic detail on dimer interface for these variants"]},{"year":2017,"claim":"Established that BRAF is expressed as multiple C-terminal isoforms whose abundance is post-translationally controlled, with BRAF-X2 selectively degraded by the proteasome.","evidence":"RNA-seq across cancer patients, isoform-specific protein detection, proteasome inhibition, and functional isoform assays","pmids":["28454577"],"confidence":"Medium","gaps":["Ligase mediating BRAF-X2 degradation unidentified","Functional consequence of isoform balance in tumors unclear"]},{"year":2018,"claim":"Provided the mechanistic basis for dimer-selective RAF inhibition, showing PLX8394 disrupts BRAF-containing dimers via N-lobe sequence differences while sparing other RAF dimers, broadening the targetable mutant spectrum.","evidence":"Cell-based signaling and dimer disruption assays, RAF isoform structure-activity and mutagenesis, diverse BRAF-variant cell panels","pmids":["30559419"],"confidence":"High","gaps":["In vivo efficacy across variant classes not fully mapped","Resistance to dimer-selective inhibitors not addressed"]},{"year":2019,"claim":"Defined structural and allosteric determinants of inhibitor action: a αC-helix allosteric site supporting intra-dimer positive cooperativity, and inhibitor-stabilized inactive conformations that enhance RAS:BRAF binding to promote paradoxical activation.","evidence":"Structural binding and αC-helix conformation analysis with PHI1 development (2020); luciferase conformation biosensors and RAS:RAF binary interaction assays in melanoma cells (2019)","pmids":["32873792","31453322"],"confidence":"Medium","gaps":["Biosensor-based allosteric communication is partly inferred","Single-lab structural models await orthogonal confirmation"]},{"year":2019,"claim":"Identified adaptive resistance routes that reactivate ERK or bypass it: autocrine FGF1-FGFR signaling restores ERK under BRAF/MEK inhibition.","evidence":"Resistant line generation, synthetic-lethal screen, FGF1 transcriptional analysis, FGFR inhibitor rescue in cells and PDX","pmids":["31515463"],"confidence":"Medium","gaps":["Single lab","Transcriptional driver of FGF1 upregulation not defined"]},{"year":2023,"claim":"Extended the resistance landscape beyond ERK by showing SRC activation, driven by a COX2/PGE2 autocrine loop, reprograms transcription via β-catenin to sustain BRAF-mutant colorectal cancer under targeted therapy.","evidence":"Kinase activity mapping, β-catenin reporter, COX2/PGE2 analysis, and PDX combination treatment","pmids":["36759733"],"confidence":"Medium","gaps":["Single lab","Mechanism coupling SRC to COX2 induction not fully resolved"]},{"year":null,"claim":"How the regulatory inputs (AMPK/14-3-3, metabolite loops, isoform balance) integrate with the diverse oncogenic signaling modes (monomer, dimer, kinase-dead/CRAF) to determine inhibitor response and resistance in vivo remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking conformation, dimerization, and RAS binding across mutant classes","Predictive markers distinguishing FGFR- vs SRC- vs RBD-deletion resistance lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,7]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,7]}],"localization":[],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,9,16]}],"complexes":[],"partners":["MEK1","KSR1","CRAF","14-3-3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P15056","full_name":"Serine/threonine-protein kinase B-raf","aliases":["Proto-oncogene B-Raf","p94","v-Raf murine sarcoma viral oncogene homolog B1"],"length_aa":766,"mass_kda":84.4,"function":"Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)","subcellular_location":"Nucleus; Cytoplasm; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P15056/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRAF","classification":"Not Classified","n_dependent_lines":115,"n_total_lines":1208,"dependency_fraction":0.09519867549668874},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MAP2K1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BRAF","total_profiled":1310},"omim":[{"mim_id":"620929","title":"MOB KINASE ACTIVATOR 3A; MOB3A","url":"https://www.omim.org/entry/620929"},{"mim_id":"620412","title":"NONCODING RNA ASSOCIATED WITH MAP KINASE PATHWAY AND GROWTH ARREST; NAMA","url":"https://www.omim.org/entry/620412"},{"mim_id":"619589","title":"BRAF-ACTIVATED NONCODING RNA; BANCR","url":"https://www.omim.org/entry/619589"},{"mim_id":"617108","title":"SESSILE SERRATED POLYPOSIS CANCER SYNDROME; SSPCS","url":"https://www.omim.org/entry/617108"},{"mim_id":"617057","title":"CYTOSOLIC THIOURIDYLASE, SUBUNIT 2; CTU2","url":"https://www.omim.org/entry/617057"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRAF"},"hgnc":{"alias_symbol":["BRAF1","BRAF-1"],"prev_symbol":[]},"alphafold":{"accession":"P15056","domains":[{"cath_id":"3.10.20.90","chopping":"155-225","consensus_level":"medium","plddt":85.9792,"start":155,"end":225},{"cath_id":"3.30.60.20","chopping":"236-290","consensus_level":"medium","plddt":82.2804,"start":236,"end":290},{"cath_id":"3.30.200.20","chopping":"450-531","consensus_level":"medium","plddt":85.9628,"start":450,"end":531},{"cath_id":"1.10.510.10","chopping":"535-721","consensus_level":"medium","plddt":88.0211,"start":535,"end":721},{"cath_id":"1.10.287","chopping":"43-102","consensus_level":"high","plddt":81.6427,"start":43,"end":102}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15056","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15056-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15056-F1-predicted_aligned_error_v6.png","plddt_mean":66.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRAF","jax_strain_url":"https://www.jax.org/strain/search?query=BRAF"},"sequence":{"accession":"P15056","fasta_url":"https://rest.uniprot.org/uniprotkb/P15056.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15056/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15056"}},"corpus_meta":[{"pmid":"12068308","id":"PMC_12068308","title":"Mutations of the BRAF gene in human cancer.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12068308","citation_count":8391,"is_preprint":false},{"pmid":"23020132","id":"PMC_23020132","title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23020132","citation_count":2221,"is_preprint":false},{"pmid":"25265494","id":"PMC_25265494","title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25265494","citation_count":1662,"is_preprint":false},{"pmid":"25265492","id":"PMC_25265492","title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25265492","citation_count":1522,"is_preprint":false},{"pmid":"16273091","id":"PMC_16273091","title":"BRAF mutation predicts sensitivity to MEK inhibition.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16273091","citation_count":1092,"is_preprint":false},{"pmid":"15947100","id":"PMC_15947100","title":"BRAF mutation in thyroid cancer.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15947100","citation_count":1052,"is_preprint":false},{"pmid":"12697856","id":"PMC_12697856","title":"BRAF mutation in papillary thyroid carcinoma.","date":"2003","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/12697856","citation_count":673,"is_preprint":false},{"pmid":"22554099","id":"PMC_22554099","title":"The role of BRAF V600 mutation in melanoma.","date":"2012","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22554099","citation_count":609,"is_preprint":false},{"pmid":"29431699","id":"PMC_29431699","title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29431699","citation_count":487,"is_preprint":false},{"pmid":"26392102","id":"PMC_26392102","title":"Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26392102","citation_count":426,"is_preprint":false},{"pmid":"31171879","id":"PMC_31171879","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31171879","citation_count":267,"is_preprint":false},{"pmid":"32540454","id":"PMC_32540454","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32540454","citation_count":265,"is_preprint":false},{"pmid":"24993163","id":"PMC_24993163","title":"Activating FGFR2-RAS-BRAF mutations in ameloblastoma.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24993163","citation_count":219,"is_preprint":false},{"pmid":"17724477","id":"PMC_17724477","title":"BRAF(E600) in benign and malignant human tumours.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17724477","citation_count":215,"is_preprint":false},{"pmid":"27429963","id":"PMC_27429963","title":"Resistant mechanisms to BRAF inhibitors in melanoma.","date":"2016","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27429963","citation_count":182,"is_preprint":false},{"pmid":"16845322","id":"PMC_16845322","title":"BRAF and NRAS mutations in melanoma and melanocytic nevi.","date":"2006","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/16845322","citation_count":181,"is_preprint":false},{"pmid":"30559419","id":"PMC_30559419","title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.","date":"2018","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30559419","citation_count":161,"is_preprint":false},{"pmid":"19464601","id":"PMC_19464601","title":"BRAF signaling and targeted therapies in melanoma.","date":"2009","source":"Hematology/oncology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/19464601","citation_count":150,"is_preprint":false},{"pmid":"26145173","id":"PMC_26145173","title":"Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26145173","citation_count":136,"is_preprint":false},{"pmid":"20350535","id":"PMC_20350535","title":"BRAF as therapeutic target in melanoma.","date":"2010","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20350535","citation_count":134,"is_preprint":false},{"pmid":"32645969","id":"PMC_32645969","title":"BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32645969","citation_count":132,"is_preprint":false},{"pmid":"23594689","id":"PMC_23594689","title":"Clinicopathological relevance of BRAF mutations in human cancer.","date":"2013","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23594689","citation_count":127,"is_preprint":false},{"pmid":"26396549","id":"PMC_26396549","title":"BRAF Mutation in Colorectal Cancer: An Update.","date":"2015","source":"Biomarkers in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26396549","citation_count":116,"is_preprint":false},{"pmid":"24095280","id":"PMC_24095280","title":"Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24095280","citation_count":116,"is_preprint":false},{"pmid":"29488071","id":"PMC_29488071","title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.","date":"2018","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29488071","citation_count":113,"is_preprint":false},{"pmid":"26053201","id":"PMC_26053201","title":"BRAF Mutations in Canine Cancers.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26053201","citation_count":105,"is_preprint":false},{"pmid":"30224342","id":"PMC_30224342","title":"Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30224342","citation_count":105,"is_preprint":false},{"pmid":"25344914","id":"PMC_25344914","title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25344914","citation_count":104,"is_preprint":false},{"pmid":"29114545","id":"PMC_29114545","title":"Overcoming resistance to BRAF inhibitors.","date":"2017","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29114545","citation_count":97,"is_preprint":false},{"pmid":"21900390","id":"PMC_21900390","title":"Role of BRAF in thyroid oncogenesis.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21900390","citation_count":97,"is_preprint":false},{"pmid":"23242278","id":"PMC_23242278","title":"To BRAF or not to BRAF: is that even a question anymore?","date":"2013","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23242278","citation_count":95,"is_preprint":false},{"pmid":"26498038","id":"PMC_26498038","title":"Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26498038","citation_count":94,"is_preprint":false},{"pmid":"24325952","id":"PMC_24325952","title":"BRAF inhibitors in cancer therapy.","date":"2013","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24325952","citation_count":89,"is_preprint":false},{"pmid":"28783725","id":"PMC_28783725","title":"A Braf kinase-inactive mutant induces lung adenocarcinoma.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28783725","citation_count":87,"is_preprint":false},{"pmid":"36842301","id":"PMC_36842301","title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.","date":"2023","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/36842301","citation_count":84,"is_preprint":false},{"pmid":"16567964","id":"PMC_16567964","title":"BRAF somatic mutations in malignant melanoma and melanocytic naevi.","date":"2006","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/16567964","citation_count":84,"is_preprint":false},{"pmid":"23617957","id":"PMC_23617957","title":"B-Raf and the inhibitors: from bench to bedside.","date":"2013","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23617957","citation_count":83,"is_preprint":false},{"pmid":"16299399","id":"PMC_16299399","title":"Alterations of the BRAF gene in thyroid tumors.","date":"2005","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16299399","citation_count":83,"is_preprint":false},{"pmid":"29461827","id":"PMC_29461827","title":"Current Insights of BRAF Inhibitors in Cancer.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29461827","citation_count":82,"is_preprint":false},{"pmid":"33801689","id":"PMC_33801689","title":"BRAF Gene and Melanoma: Back to the Future.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33801689","citation_count":81,"is_preprint":false},{"pmid":"17179987","id":"PMC_17179987","title":"Targeting BRAF in thyroid cancer.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17179987","citation_count":80,"is_preprint":false},{"pmid":"23549875","id":"PMC_23549875","title":"Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23549875","citation_count":75,"is_preprint":false},{"pmid":"30157175","id":"PMC_30157175","title":"BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.","date":"2018","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/30157175","citation_count":74,"is_preprint":false},{"pmid":"25385327","id":"PMC_25385327","title":"Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25385327","citation_count":74,"is_preprint":false},{"pmid":"34636352","id":"PMC_34636352","title":"BRAF mutations in thyroid cancer.","date":"2022","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34636352","citation_count":69,"is_preprint":false},{"pmid":"26150740","id":"PMC_26150740","title":"BRAF gene: From human cancers to developmental syndromes.","date":"2014","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26150740","citation_count":68,"is_preprint":false},{"pmid":"27681305","id":"PMC_27681305","title":"BRAF-V600E expression correlates with ameloblastoma aggressiveness.","date":"2016","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27681305","citation_count":65,"is_preprint":false},{"pmid":"32873792","id":"PMC_32873792","title":"Inhibitors of BRAF dimers using an allosteric site.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32873792","citation_count":65,"is_preprint":false},{"pmid":"18644254","id":"PMC_18644254","title":"Therapeutic strategies for inhibiting oncogenic BRAF signaling.","date":"2008","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18644254","citation_count":65,"is_preprint":false},{"pmid":"29674508","id":"PMC_29674508","title":"Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29674508","citation_count":64,"is_preprint":false},{"pmid":"31398831","id":"PMC_31398831","title":"Atypical BRAF and NRAS Mutations in Mucosal Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31398831","citation_count":62,"is_preprint":false},{"pmid":"26563980","id":"PMC_26563980","title":"ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26563980","citation_count":61,"is_preprint":false},{"pmid":"27747083","id":"PMC_27747083","title":"RAS and BRAF in metastatic colorectal cancer management.","date":"2016","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27747083","citation_count":59,"is_preprint":false},{"pmid":"24433452","id":"PMC_24433452","title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24433452","citation_count":58,"is_preprint":false},{"pmid":"23615632","id":"PMC_23615632","title":"CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23615632","citation_count":57,"is_preprint":false},{"pmid":"30265855","id":"PMC_30265855","title":"BRAF alterations in primary brain tumors.","date":"2018","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30265855","citation_count":55,"is_preprint":false},{"pmid":"32485528","id":"PMC_32485528","title":"A BRAF new world.","date":"2020","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32485528","citation_count":52,"is_preprint":false},{"pmid":"25648338","id":"PMC_25648338","title":"BRAF and MEK inhibition in melanoma.","date":"2015","source":"Expert opinion on drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/25648338","citation_count":52,"is_preprint":false},{"pmid":"33747149","id":"PMC_33747149","title":"BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.","date":"2021","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33747149","citation_count":51,"is_preprint":false},{"pmid":"33268358","id":"PMC_33268358","title":"BRAF inhibition protects against hearing loss in mice.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33268358","citation_count":49,"is_preprint":false},{"pmid":"27210749","id":"PMC_27210749","title":"Oncogenic BRAF-Mediated Melanoma Cell Invasion.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27210749","citation_count":46,"is_preprint":false},{"pmid":"31515463","id":"PMC_31515463","title":"Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31515463","citation_count":45,"is_preprint":false},{"pmid":"28278349","id":"PMC_28278349","title":"Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.","date":"2017","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28278349","citation_count":44,"is_preprint":false},{"pmid":"21426297","id":"PMC_21426297","title":"BRAF as a target for cancer therapy.","date":"2011","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21426297","citation_count":43,"is_preprint":false},{"pmid":"36759733","id":"PMC_36759733","title":"A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36759733","citation_count":42,"is_preprint":false},{"pmid":"34063682","id":"PMC_34063682","title":"Targeting BRAF and RAS in Colorectal Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34063682","citation_count":42,"is_preprint":false},{"pmid":"32476297","id":"PMC_32476297","title":"BRAF mutation and its inhibitors in sarcoma treatment.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32476297","citation_count":41,"is_preprint":false},{"pmid":"28679432","id":"PMC_28679432","title":"New somatic BRAF splicing mutation in Langerhans cell histiocytosis.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28679432","citation_count":41,"is_preprint":false},{"pmid":"24352648","id":"PMC_24352648","title":"Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24352648","citation_count":41,"is_preprint":false},{"pmid":"27169980","id":"PMC_27169980","title":"BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27169980","citation_count":40,"is_preprint":false},{"pmid":"35413124","id":"PMC_35413124","title":"Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.","date":"2022","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35413124","citation_count":38,"is_preprint":false},{"pmid":"33558987","id":"PMC_33558987","title":"BRAF Heterogeneity in Melanoma.","date":"2021","source":"Current treatment options in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33558987","citation_count":37,"is_preprint":false},{"pmid":"22349616","id":"PMC_22349616","title":"Autoantibodies to PAD4 and BRAF in rheumatoid arthritis.","date":"2012","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22349616","citation_count":37,"is_preprint":false},{"pmid":"26851802","id":"PMC_26851802","title":"Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.","date":"2016","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/26851802","citation_count":36,"is_preprint":false},{"pmid":"24857135","id":"PMC_24857135","title":"Targeting BRAF in pediatric brain tumors.","date":"2014","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/24857135","citation_count":35,"is_preprint":false},{"pmid":"33260892","id":"PMC_33260892","title":"BRAF: A Two-Faced Janus.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33260892","citation_count":34,"is_preprint":false},{"pmid":"31581557","id":"PMC_31581557","title":"Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31581557","citation_count":34,"is_preprint":false},{"pmid":"18473997","id":"PMC_18473997","title":"Therapeutic strategies for targeting BRAF in human cancer.","date":"2007","source":"Reviews on recent clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/18473997","citation_count":34,"is_preprint":false},{"pmid":"26384810","id":"PMC_26384810","title":"Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.","date":"2015","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26384810","citation_count":34,"is_preprint":false},{"pmid":"25961545","id":"PMC_25961545","title":"The role of BRAF in the pathogenesis of thyroid carcinoma.","date":"2015","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/25961545","citation_count":32,"is_preprint":false},{"pmid":"22369373","id":"PMC_22369373","title":"BRAF mutation testing in clinical practice.","date":"2012","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/22369373","citation_count":32,"is_preprint":false},{"pmid":"27848137","id":"PMC_27848137","title":"Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.","date":"2016","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27848137","citation_count":32,"is_preprint":false},{"pmid":"17956344","id":"PMC_17956344","title":"Mouse models for BRAF-induced cancers.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17956344","citation_count":32,"is_preprint":false},{"pmid":"21393075","id":"PMC_21393075","title":"Biological challenges of BRAF inhibitor therapy.","date":"2011","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21393075","citation_count":31,"is_preprint":false},{"pmid":"29061943","id":"PMC_29061943","title":"Comparative Aspects of BRAF Mutations in Canine Cancers.","date":"2015","source":"Veterinary sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29061943","citation_count":31,"is_preprint":false},{"pmid":"31391125","id":"PMC_31391125","title":"TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31391125","citation_count":31,"is_preprint":false},{"pmid":"29171936","id":"PMC_29171936","title":"BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.","date":"2017","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/29171936","citation_count":31,"is_preprint":false},{"pmid":"27341594","id":"PMC_27341594","title":"BRAF-Directed Therapy in Metastatic Colorectal Cancer.","date":"2016","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/27341594","citation_count":30,"is_preprint":false},{"pmid":"31453322","id":"PMC_31453322","title":"BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31453322","citation_count":29,"is_preprint":false},{"pmid":"26014474","id":"PMC_26014474","title":"BRAF mutations in pediatric metanephric tumors.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26014474","citation_count":29,"is_preprint":false},{"pmid":"25957797","id":"PMC_25957797","title":"BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.","date":"2015","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25957797","citation_count":29,"is_preprint":false},{"pmid":"22157295","id":"PMC_22157295","title":"BRAF inhibitors and melanoma.","date":"2011","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/22157295","citation_count":28,"is_preprint":false},{"pmid":"28454577","id":"PMC_28454577","title":"The landscape of BRAF transcript and protein variants in human cancer.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28454577","citation_count":28,"is_preprint":false},{"pmid":"29667105","id":"PMC_29667105","title":"The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma.","date":"2018","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29667105","citation_count":28,"is_preprint":false},{"pmid":"34923978","id":"PMC_34923978","title":"Epigenetic modification and BRAF gene mutation in thyroid carcinoma.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34923978","citation_count":27,"is_preprint":false},{"pmid":"24495477","id":"PMC_24495477","title":"BRAF--a new player in hematological neoplasms.","date":"2014","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24495477","citation_count":27,"is_preprint":false},{"pmid":"28282860","id":"PMC_28282860","title":"Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28282860","citation_count":27,"is_preprint":false},{"pmid":"27097112","id":"PMC_27097112","title":"Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27097112","citation_count":27,"is_preprint":false},{"pmid":"35135122","id":"PMC_35135122","title":"BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.","date":"2018","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35135122","citation_count":27,"is_preprint":false},{"pmid":"34831014","id":"PMC_34831014","title":"IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34831014","citation_count":26,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43950,"output_tokens":5055,"usd":0.103837,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13554,"output_tokens":4199,"usd":0.086373,"stage2_stop_reason":"end_turn"},"total_usd":0.19021,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"BRAF somatic missense mutations occur in 66% of malignant melanomas, predominantly within the kinase domain; mutated BRAF proteins (including V599E/V600E) have elevated kinase activity and are transforming in NIH3T3 cells; RAS function is not required for growth of cancer cell lines with the V600E mutation, establishing BRAF as a constitutively active, RAS-independent oncogenic kinase.\",\n      \"method\": \"Genome-wide sequencing of cancer samples, in vitro kinase activity assays, NIH3T3 transformation assays, cancer cell line growth studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis, transformation assay, and genetic epistasis (RAS independence); foundational study replicated extensively across many labs\",\n      \"pmids\": [\"12068308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRAF mutation (V600E) confers selective sensitivity to MEK inhibition regardless of tissue lineage; pharmacological MEK inhibition completely abrogated tumor growth in BRAF-mutant xenografts, correlating with downregulation of cyclin D1 and G1 arrest, establishing BRAF-mutant tumors as exquisitely MEK-dependent.\",\n      \"method\": \"Small-molecule MEK inhibitor treatment of cell lines and xenografts stratified by BRAF/RAS mutation status; cyclin D1 expression analysis; cell-cycle analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic stratification, pharmacologic inhibition in vitro and in vivo with defined molecular readouts; replicated in subsequent studies\",\n      \"pmids\": [\"16273091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRAF is phosphorylated at Ser729 by AMP-activated protein kinase (AMPK); this phosphorylation promotes association of BRAF with 14-3-3 proteins and disrupts its interaction with the KSR1 scaffolding protein, leading to attenuation of MEK-ERK signaling, impaired keratinocyte proliferation, and suppression of BRAF inhibitor-induced ERK hyperactivation.\",\n      \"method\": \"In vitro kinase assay (AMPK phosphorylation of BRAF), co-immunoprecipitation (BRAF–14-3-3 and BRAF–KSR1 interactions), site-specific mutagenesis, cell-cycle analysis, mouse skin epidermal hyperplasia model\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay identifying specific phosphorylation site, reciprocal co-IP for binding partners, mutagenesis, and in vivo mouse model in a single study\",\n      \"pmids\": [\"24095280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Oncogenic BRAF V600E upregulates the ketogenic enzyme HMGCL via the transcription factor Oct-1, leading to increased intracellular acetoacetate levels; acetoacetate selectively enhances binding of BRAF V600E (but not wild-type BRAF) to MEK1, promoting MEK-ERK signaling and tumor growth — a mutation-specific metabolic rewiring mechanism.\",\n      \"method\": \"Co-immunoprecipitation (BRAF V600E–MEK1 binding with/without acetoacetate), shRNA knockdown of HMGCL, metabolite measurement, Oct-1 transcriptional analysis, xenograft tumor growth assay\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution of metabolite-enhanced BRAF–MEK1 binding, mutagenesis-like comparison of V600E vs WT, multiple orthogonal methods in single study\",\n      \"pmids\": [\"26145173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PLX8394, a next-generation RAF inhibitor, inhibits ERK signaling by specifically disrupting BRAF-containing dimers (BRAF homodimers and BRAF-CRAF heterodimers) but not CRAF homodimers or ARAF-containing dimers; differences in the N-terminal portion of the kinase domain among RAF isoforms are responsible for this differential vulnerability; PLX8394 inhibits ERK signaling in tumors driven by dimeric BRAF mutants (fusions, splice variants) as well as V600 monomers.\",\n      \"method\": \"Cell-based signaling assays, RAF dimer disruption assays, structure-activity analysis of RAF isoform sequences, mutagenesis, cancer cell line panels with diverse BRAF alterations\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection of dimer selectivity with isoform mutagenesis and multiple BRAF-variant cell models in a single focused study\",\n      \"pmids\": [\"30559419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ponatinib binds the BRAF dimer and stabilizes a distinct αC-helix conformation through interaction with a previously unrevealed allosteric site; based on this structural insight, PHI1 was developed as a BRAF dimer-selective inhibitor that shows enhanced inhibition of the second protomer when the first is occupied (positive cooperativity within the dimer).\",\n      \"method\": \"Structural binding studies, αC-helix conformation analysis, development of PHI1 inhibitor, cellular selectivity assays for BRAF monomers vs. dimers\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural characterization of allosteric site combined with medicinal chemistry validation and cellular functional assays in single study\",\n      \"pmids\": [\"32873792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRAF inhibitors binding the V600E-mutated BRAF catalytic pocket stabilize an intermediate, inactive kinase conformation that unexpectedly enhances binary RAS:BRAF interactions independently of RAF dimerization in melanoma cells; this allosteric intramolecular communication between the kinase and RAS-binding domains may further promote paradoxical kinase activation.\",\n      \"method\": \"Luciferase-based BRAF conformation biosensors, RAS:RAF binary interaction assays, structurally diverse inhibitor panel, melanoma cell lines\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel biosensor approach with multiple inhibitors, but mechanistic interpretation (allosteric communication) is partially inferred; single lab\",\n      \"pmids\": [\"31453322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRAF V600E drives melanoma cell invasion by inducing phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics (F-actin/cortactin foci, membrane protrusion) and matrix metalloprotease secretion, respectively; BRAF V600E inhibition blocks these invasion activities in vitro and reduces cortactin foci in a murine melanoma model and patient biopsies.\",\n      \"method\": \"F-actin/cortactin foci assays, ECM degradation assay, BRAF inhibitor treatment, phospho-protein analysis, genome-wide expression profiling, murine BRAF V600E model, patient biopsy analysis\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined molecular mechanism (ERK-mediated phosphorylation of cortactin/Exo70) with functional readouts in vitro, in vivo, and in patient tissue; single lab\",\n      \"pmids\": [\"27210749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Expression of the kinase-inactive Braf D631A (human D594A) isoform in mice triggers lung adenocarcinoma in vivo, acting as an initiating oncogenic event; co-expression with Kras G12V markedly enhances tumor initiation via Craf kinase activity; wild-type Braf kinase sustains Kras/Braf D631A-driven tumors, and its ablation induces excessive MAPK signaling causing oncogenic toxicity that can be rescued by Mek inhibition.\",\n      \"method\": \"Conditional knock-in mouse model (Cre-mediated), genetic epistasis (wild-type Braf allele deletion, Craf activity requirement), MEK inhibitor rescue experiments, MAPK pathway signaling analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous mouse genetic epistasis with multiple allele combinations, pharmacological rescue, and in vivo oncogenesis readout; comprehensive mechanistic dissection in single study\",\n      \"pmids\": [\"28783725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRAF gene internal deletions involving the Ras-binding domain (exons 2–8) represent a mechanism of acquired resistance to dabrafenib/trametinib in melanoma; these deletions are analogous to BRAF fusions and splice variants that reactivate RAS-RAF-MEK-ERK signaling by removing the RAS-binding domain.\",\n      \"method\": \"Pre- and post-treatment tumor biopsy sequencing (foundation medicine panel), large melanoma cohort analysis (next-generation sequencing)\",\n      \"journal\": \"Pigment Cell & Melanoma Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genomic characterization with mechanistic inference from structural analogy to known splice variants; no direct functional reconstitution of the deletion construct\",\n      \"pmids\": [\"29171936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A somatic BRAF splicing mutation (9 bp duplication encoding insertion of 3 amino acids in the N-terminal kinase domain lobe, p.Arg506_Lys507insLeuLeuArg) found in LCH cases enhances MAPK pathway activation in HEK293 cells and is not inhibited by vemurafenib but is inhibited by the dimer-targeting inhibitor PLX8394, indicating this mutant signals as a dimer.\",\n      \"method\": \"Whole exome sequencing, transient expression in HEK293 cells, MAPK pathway activation assays, BRAF inhibitor treatment (vemurafenib vs PLX8394)\",\n      \"journal\": \"Molecular Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — cell-based functional validation of mutant with inhibitor sensitivity, but single lab and limited mechanistic detail in abstract\",\n      \"pmids\": [\"28679432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Anti-BRAF autoantibodies targeting the BRAF catalytic domain were identified in rheumatoid arthritis patients; these autoantibodies stimulate BRAF activity, in contrast to anti-PAD4 autoantibodies which are inhibitory.\",\n      \"method\": \"Protein array screening of 8000 human proteins with RA patient sera, validation of BRAF as autoantigen, functional assay of antibody effect on BRAF kinase activity\",\n      \"journal\": \"Autoimmunity Reviews\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, functional claim (stimulation of BRAF activity) mentioned briefly in abstract without detailed mechanistic follow-up\",\n      \"pmids\": [\"22349616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRAF oncogene drives loss of RIPK3 expression in cancer cells, suppressing necroptosis sensitivity; inhibition of BRAF can rescue RIPK3 expression and restore necroptosis sensitivity.\",\n      \"method\": \"Genome-wide bioinformatics analysis of 941 cancer cell line necroptosis sensitivity screen correlated with gene expression and mutation data; pharmacological BRAF inhibition with RIPK3 re-expression readout\",\n      \"journal\": \"PLoS Biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — correlational bioinformatics with pharmacological rescue as primary evidence; mechanism of BRAF-driven RIPK3 silencing not directly established\",\n      \"pmids\": [\"30157175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRAF V600E mutations drive constitutive MAPK pathway activation in ameloblastoma cells in vitro; the BRAF inhibitor vemurafenib potently inhibits proliferation and MAPK activation in an ameloblastoma-derived cell line.\",\n      \"method\": \"Allele-specific PCR, Sanger sequencing, VE1 immunohistochemistry, cell proliferation assay with vemurafenib, phospho-MAPK western blot in cell line\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutation identification with functional validation in cell line model; two orthogonal detection methods plus inhibitor functional assay\",\n      \"pmids\": [\"24993163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRAF V600E inhibition attenuates TERT expression and TERT promoter activity in BRAF V600E/TERT promoter double-mutant glioma cells but not in BRAF V600E-only cells; this occurs through downregulation of ETS1 phosphorylation and expression, with ChIP confirming a functional role for ETS1 at the TERT promoter.\",\n      \"method\": \"BRAF inhibitor treatment, qRT-PCR, Western blot (ETS1 expression/phosphorylation), ChIP, luciferase TERT promoter reporter assay, ETS1 knockdown experiments\",\n      \"journal\": \"Acta Neuropathologica Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP, reporter assay, KD, inhibitor) establishing BRAF→ERK→ETS1→TERT axis in single lab study\",\n      \"pmids\": [\"31391125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SRC kinases are systematically activated in BRAF V600E colorectal cancer following BRAF ± EGFR targeted inhibition; SRC drives resistance independently of ERK signaling by inducing transcriptional reprogramming through β-catenin; this SRC activation is mediated by an autocrine prostaglandin E2 (COX2) loop, and COX2 inhibition combined with BRAF + EGFR targeting promotes durable tumor suppression in PDX models.\",\n      \"method\": \"High-throughput kinase activity mapping, cell-based signaling assays, β-catenin transcriptional reporter, COX2/prostaglandin E2 pathway analysis, patient-derived xenograft models\",\n      \"journal\": \"Nature Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods identifying SRC-β-catenin resistance axis and COX2 autocrine loop; in vivo PDX validation; single lab\",\n      \"pmids\": [\"36759733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In BRAF V600E-driven tumors, adaptive resistance to dual BRAF/MEK inhibition occurs through transcriptional upregulation of FGF1, which autocrinally activates FGFR to reactivate ERK; FGFR inhibition overcomes this resistance in cell lines and patient-derived xenograft models.\",\n      \"method\": \"Resistant cell line generation, pharmacologic synthetic lethal screen, FGF1 transcriptional analysis, FGFR inhibitor rescue in cells and PDX models, serum FGF1 clinical correlation\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanism established through resistant line generation, transcriptomic analysis, and PDX validation; single lab\",\n      \"pmids\": [\"31515463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Dabrafenib (BRAF kinase inhibitor) and other BRAF/MEK/ERK pathway inhibitors protect against cisplatin- and noise-induced hearing loss in mice; oral dabrafenib represses ERK phosphorylation in cochlear cells, identifying BRAF-ERK signaling as a mediator of ototoxicity.\",\n      \"method\": \"Small-molecule kinase inhibitor screen in inner ear cell line, cochlear explant hair cell death assay, oral dabrafenib treatment in adult mice, ERK phosphorylation analysis in cochlear cells, audiological hearing loss assessment\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological evidence linking BRAF-ERK pathway to cochlear cell survival, multiple model systems; single lab\",\n      \"pmids\": [\"33268358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRAF exists as a pool of at least three protein isoforms (BRAF-ref, BRAF-X1, BRAF-X2) differing in their C-terminal coding sequences; BRAF-X1 and BRAF-ref are both translated and together account for BRAF functional activities, while endogenous BRAF-X2 protein is selectively targeted for degradation by the ubiquitin-proteasome pathway.\",\n      \"method\": \"RNA-seq analysis of >4800 cancer patients, isoform-specific protein detection, proteasome inhibition experiments, functional activity assays of isoforms\",\n      \"journal\": \"Molecular Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein-level isoform characterization with degradation mechanism (proteasome) validated biochemically; large dataset plus functional follow-up\",\n      \"pmids\": [\"28454577\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRAF is a RAS-regulated serine/threonine kinase that, when activated (most commonly by the V600E mutation), signals constitutively as an active monomer (V600E) or as RAS-independent dimers (other oncogenic mutants and fusions) through MEK-ERK to drive proliferation, survival, invasion (via ERK-mediated cortactin/Exo70 phosphorylation), and metabolic rewiring (via Oct-1–HMGCL–acetoacetate–MEK1 axis); its activity is negatively regulated by AMPK-mediated phosphorylation at Ser729, which promotes 14-3-3 binding and disrupts KSR1 scaffolding; pharmacological inhibitors variably target monomers or dimers depending on their mechanism, and resistance arises through FGFR autocrine loops, RAS-binding domain deletions, and other MAPK reactivation mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRAF is a RAS-regulated serine/threonine kinase that functions as a core node of the MAPK (RAS-RAF-MEK-ERK) cascade and is a major oncogenic driver, most prominently through the recurrent V600E mutation that elevates kinase activity, transforms cells, and signals constitutively without requiring upstream RAS function [#0]. BRAF-mutant tumors across lineages are exquisitely dependent on downstream MEK, such that MEK inhibition arrests proliferation via cyclin D1 downregulation and G1 arrest [#1], and the same dependence drives MAPK activation in diverse tumor contexts including ameloblastoma [#13]. The oncogenic output of BRAF V600E extends beyond proliferation: ERK-mediated phosphorylation of cortactin and the exocyst subunit Exo70 reprograms actin dynamics and matrix metalloprotease secretion to drive invasion [#7], an ETS1-dependent axis sustains TERT promoter activity [#14], and a mutation-specific metabolic loop in which Oct-1 drives HMGCL expression and acetoacetate selectively enhances V600E-MEK1 binding amplifies signaling [#3]. BRAF activity is negatively regulated by AMPK phosphorylation at Ser729, which promotes 14-3-3 association, disrupts KSR1 scaffolding, and attenuates MEK-ERK signaling [#2]. Distinct oncogenic mechanisms operate for non-V600 alterations: kinase-inactive BRAF can initiate tumorigenesis through CRAF, with wild-type BRAF kinase paradoxically required to restrain excessive MAPK output [#8], and RAS-binding-domain deletions, splice insertions, and fusions activate signaling as RAF dimers that resist V600-monomer inhibitors but are blocked by dimer-disrupting agents [#9, #10, #4]. Structural work defines the basis for monomer- versus dimer-selective inhibition, including an allosteric αC-helix site supporting positive cooperativity within the dimer [#5] and inhibitor-stabilized inactive conformations that enhance RAS:BRAF binding [#6]. Adaptive and acquired resistance to pathway inhibition arises through autocrine FGF1-FGFR reactivation of ERK [#16] and an ERK-independent SRC-β-catenin axis sustained by a COX2/prostaglandin E2 loop [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that BRAF is a frequently mutated oncogenic kinase whose activating mutations render it constitutively active and independent of upstream RAS, defining it as a direct cancer driver rather than a passive relay.\",\n      \"evidence\": \"Genome-wide cancer sequencing with in vitro kinase assays, NIH3T3 transformation, and RAS-independence growth studies in melanoma\",\n      \"pmids\": [\"12068308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how different mutation classes signal (monomer vs dimer)\", \"No structural basis for elevated kinase activity\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that BRAF mutation creates a lineage-independent therapeutic dependence on MEK, framing BRAF-mutant tumors as targetable through the downstream MAPK module.\",\n      \"evidence\": \"MEK inhibitor treatment of cell lines and xenografts stratified by BRAF/RAS status, with cyclin D1 and cell-cycle readouts\",\n      \"pmids\": [\"16273091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address acquired resistance\", \"MEK dependence shown but BRAF-direct inhibition strategy not yet defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified a physiological brake on BRAF: AMPK phosphorylation at Ser729 reroutes BRAF away from KSR1 scaffolding toward 14-3-3, attenuating MAPK output and constraining BRAF-inhibitor-induced ERK hyperactivation.\",\n      \"evidence\": \"In vitro AMPK kinase assay, reciprocal co-IP of 14-3-3 and KSR1, site mutagenesis, and a mouse epidermal hyperplasia model\",\n      \"pmids\": [\"24095280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance of Ser729 regulation in tumors with constitutive V600E unclear\", \"How AMPK status modulates inhibitor response in patients not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a mutation-specific metabolic feed-forward loop in which BRAF V600E induces ketogenic HMGCL via Oct-1, and the resulting acetoacetate selectively strengthens V600E-MEK1 binding to amplify signaling.\",\n      \"evidence\": \"Co-IP of V600E-MEK1 with/without acetoacetate, HMGCL shRNA, metabolite measurement, and xenograft growth\",\n      \"pmids\": [\"26145173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for acetoacetate-enhanced binding not resolved\", \"Generalizability to non-melanoma V600E tumors untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected BRAF V600E signaling to the invasive phenotype by showing ERK-driven phosphorylation of cortactin and Exo70 controls actin dynamics and MMP secretion.\",\n      \"evidence\": \"F-actin/cortactin foci and ECM degradation assays, phospho-protein analysis, BRAF inhibition, murine model and patient biopsies\",\n      \"pmids\": [\"27210749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct kinase-substrate relationship of ERK to Exo70/cortactin inferred from phospho-readouts\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that kinase-inactive BRAF can initiate tumorigenesis through CRAF and that wild-type BRAF kinase paradoxically restrains MAPK signaling, exposing dimer- and isoform-dependent complexity in BRAF oncogenesis.\",\n      \"evidence\": \"Conditional knock-in mouse genetics with allele combinations, CRAF-activity epistasis, and MEK-inhibitor rescue\",\n      \"pmids\": [\"28783725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of wild-type BRAF restraining MAPK not fully defined\", \"Human relevance of D594A-class mutants in this model untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterized RAS-binding-domain-removing alterations — internal deletions and splice insertions — as dimer-driven signaling mechanisms underlying targeted-therapy resistance.\",\n      \"evidence\": \"Pre/post-treatment tumor sequencing for deletions; HEK293 expression and inhibitor (vemurafenib vs PLX8394) testing of an LCH splice insertion\",\n      \"pmids\": [\"29171936\", \"28679432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Deletion constructs not functionally reconstituted\", \"Limited mechanistic detail on dimer interface for these variants\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established that BRAF is expressed as multiple C-terminal isoforms whose abundance is post-translationally controlled, with BRAF-X2 selectively degraded by the proteasome.\",\n      \"evidence\": \"RNA-seq across cancer patients, isoform-specific protein detection, proteasome inhibition, and functional isoform assays\",\n      \"pmids\": [\"28454577\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ligase mediating BRAF-X2 degradation unidentified\", \"Functional consequence of isoform balance in tumors unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided the mechanistic basis for dimer-selective RAF inhibition, showing PLX8394 disrupts BRAF-containing dimers via N-lobe sequence differences while sparing other RAF dimers, broadening the targetable mutant spectrum.\",\n      \"evidence\": \"Cell-based signaling and dimer disruption assays, RAF isoform structure-activity and mutagenesis, diverse BRAF-variant cell panels\",\n      \"pmids\": [\"30559419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy across variant classes not fully mapped\", \"Resistance to dimer-selective inhibitors not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined structural and allosteric determinants of inhibitor action: a αC-helix allosteric site supporting intra-dimer positive cooperativity, and inhibitor-stabilized inactive conformations that enhance RAS:BRAF binding to promote paradoxical activation.\",\n      \"evidence\": \"Structural binding and αC-helix conformation analysis with PHI1 development (2020); luciferase conformation biosensors and RAS:RAF binary interaction assays in melanoma cells (2019)\",\n      \"pmids\": [\"32873792\", \"31453322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biosensor-based allosteric communication is partly inferred\", \"Single-lab structural models await orthogonal confirmation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified adaptive resistance routes that reactivate ERK or bypass it: autocrine FGF1-FGFR signaling restores ERK under BRAF/MEK inhibition.\",\n      \"evidence\": \"Resistant line generation, synthetic-lethal screen, FGF1 transcriptional analysis, FGFR inhibitor rescue in cells and PDX\",\n      \"pmids\": [\"31515463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Transcriptional driver of FGF1 upregulation not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the resistance landscape beyond ERK by showing SRC activation, driven by a COX2/PGE2 autocrine loop, reprograms transcription via β-catenin to sustain BRAF-mutant colorectal cancer under targeted therapy.\",\n      \"evidence\": \"Kinase activity mapping, β-catenin reporter, COX2/PGE2 analysis, and PDX combination treatment\",\n      \"pmids\": [\"36759733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism coupling SRC to COX2 induction not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the regulatory inputs (AMPK/14-3-3, metabolite loops, isoform balance) integrate with the diverse oncogenic signaling modes (monomer, dimer, kinase-dead/CRAF) to determine inhibitor response and resistance in vivo remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking conformation, dimerization, and RAS binding across mutant classes\", \"Predictive markers distinguishing FGFR- vs SRC- vs RBD-deletion resistance lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 9, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MEK1\", \"KSR1\", \"CRAF\", \"14-3-3\"]\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}